• Home
  •  / Kelonia Therapeutics

Kelonia Therapeutics

  • Total Funding$50 M

OverviewSuggest Edit

Kelonia Therapeutics is a biotech company developing genetic medicines using a gene delivery platform. Its lentiviral vector (LVV) technology delivers in vivo genetic material to the target tissue. The company focuses on patients with solid tumors and hematologic cancers.

TypePrivate
Founded2017
HQCambridge, MA, USMap
Websitekeloniatx.com
View Jobs

Recent NewsAll News

Latest Updates

Employees (est.) (Jun 2022)19(+6%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Kelonia Therapeutics

Kevin Friedman

Kevin Friedman

Chief Scientific Officer, President, Director
Thomas Galbo

Thomas Galbo

Chief Business Officer
Bharat Reddy

Bharat Reddy

Vice President, Strategy and Business Development
Ryan Lynch

Ryan Lynch

Vice President of Finance
Jennifer Curry

Jennifer Curry

Vice President, HR
Shannon Grande Contrastano

Shannon Grande Contrastano

Senior Director, Preclinical Research
Show more

Kelonia Therapeutics Office Locations

Kelonia Therapeutics has an office in Cambridge
Cambridge, MA, US (HQ)
700 Main St
Show all (1)

Kelonia Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2017

Kelonia Therapeutics total Funding

$50 m

Kelonia Therapeutics latest funding size

$50 m

Time since last funding

2 months ago

Kelonia Therapeutics investors

Horizons Ventures, Venrock, Alta Partners
Kelonia Therapeutics's latest funding round in April 2022 was reported to be $50 m. In total, Kelonia Therapeutics has raised $50 m
Show all financial metrics

Kelonia Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

Learn more about our premium products
SecurityScorecard logo

Kelonia Therapeutics Online and Social Media Presence

Kelonia Therapeutics's Trends

Embed Graph

Kelonia Therapeutics News and Updates

April 29, 2022

Kelonia Therapeutics Raises $50M in Series A Financing

Kelonia Therapeutics, a Boston, MA-based biotech company focused on in vivo gene delivery, raised $50m in Series A financing

 Kelonia Therapeutics Frequently Asked Questions

  • When was Kelonia Therapeutics founded?

    Kelonia Therapeutics was founded in 2017.

  • Who are Kelonia Therapeutics key executives?

    Kelonia Therapeutics's key executives are Kevin Friedman, Thomas Galbo and Bharat Reddy.

  • How many employees does Kelonia Therapeutics have?

    Kelonia Therapeutics has 19 employees.

  • Who are Kelonia Therapeutics competitors?

    Competitors of Kelonia Therapeutics include Expression Therapeutics, Redbiotec and LXRepair.

  • Where is Kelonia Therapeutics headquarters?

    Kelonia Therapeutics headquarters is located at 700 Main St, Cambridge.

  • Where are Kelonia Therapeutics offices?

    Kelonia Therapeutics has an office in Cambridge.

  • How many offices does Kelonia Therapeutics have?

    Kelonia Therapeutics has 1 office.